You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial

  Control Tomotherapy
  n = 32 n = 37
Age   
 <50 10 15
 > = 50 22 22
Left breast tumor 16 24
Medial location 12 8
Tumor size   
 T1 (<= 20 mm) 21 26
 T2 (21–50 mm) 11 11
Nodal status, Lymph node ratio   
 pN0 21 24
 pN1, LNR 0.01-0.20 7 12
 pN1, LNR 0.21-0.65 4 1
 pN1, LNR > 0.65 0 0
Estrogen receptor positive 28 27
Progesterone receptor positive 21 25
HER2 FISH amplified 2 8
Histological grade   
 1 11 11
 2 8 18
 3 10 8
 unknown 3 0
Surgery   
 Breast conserving 21 20
Axillary lymph nodes   
 Sentinel biopsy only 20 17
 Sentinel with axillary dissection 4 6
 Immediate axillary dissection 8 14
Radio-chemotherapy schedule   
 No adjuvant chemotherapy 18 17
 RT after completion of chemotherapy 3 5
 RT concomitant with start chemotherapy 11 15
Chemotherapy type   
 Anthracycline without taxane 3 4
 Anthracycline with taxane 10 15
 CMF 1 1
Hormone therapy   
 No hormone therapy 4 10
 Tamoxifen 15 11
 Letrozole 13 11
 Zoladex 0 1
 Tamoxifen + Zoladex 0 4
 Trastuzumab 2 8